colforsin has been researched along with ticagrelor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baqi, Y; Hoffmann, K; Lutz, DA; Müller, CE; Straßburger, J; von Kügelgen, I | 1 |
| Aungraheeta, R; Butler, M; Conibear, A; Kelly, E; Mumford, A; Mundell, SJ; Nylander, S | 1 |
2 other study(ies) available for colforsin and ticagrelor
| Article | Year |
|---|---|
Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 -receptor.
Topics: Adenosine; Adenosine Diphosphate; Animals; Binding Sites; Binding, Competitive; CHO Cells; Colforsin; Cricetulus; Cyclic AMP; Dose-Response Relationship, Drug; Gene Expression Regulation; Genes, Reporter; Humans; Luciferases; Mutation; Platelet Aggregation Inhibitors; Protein Binding; Purinergic P2Y Receptor Agonists; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Response Elements; Thionucleotides; Ticagrelor; Transfection | 2014 |
Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Blood Platelets; Calcium; Calcium Signaling; Cell Adhesion Molecules; Colforsin; Cyclic AMP; Equilibrative Nucleoside Transporter 1; Female; Humans; Male; Microfilament Proteins; Phosphoproteins; Phosphorylation; Platelet Activation; Receptors, Purinergic P2Y12; Ticagrelor | 2016 |